Esperion, Inc. (ESPR) has announced a definitive agreement to acquire Corstasis, a clinical-stage biopharmaceutical company focused on innovative cardiovascular therapies. The transaction is expected to strengthen Esperion’s cardiovascular franchise with novel assets targeting lipid metabolism and inflammation.
- Esperion (ESPR) to acquire Corstasis in a $1.8 billion all-cash deal
- Upfront payment: $1.2 billion; up to $600 million in potential milestone payments
- Corstasis’ lead candidate ECT-121 in Phase 2 for residual cardiovascular risk
- Esperion’s Teflaro generated $312M in 2025 global sales
- Deal expected to close Q3 2026, pending regulatory approvals
- Esperion stock rose 8.7% on announcement, signaling positive market sentiment
Esperion, Inc. (ESPR) has entered into a definitive agreement to acquire Corstasis, a privately held biopharmaceutical company developing investigational therapies for cardiovascular disease. The all-cash transaction, valued at $1.8 billion, includes upfront consideration of $1.2 billion and potential future milestone payments of up to $600 million based on regulatory and commercial success. Corstasis' lead candidate, ECT-121, is in Phase 2 clinical development for the treatment of residual cardiovascular risk in patients with elevated triglycerides and low HDL cholesterol, a high unmet medical need in the cardiovascular space. The acquisition marks a pivotal step in Esperion’s strategy to expand its cardiovascular franchise beyond its current marketed product, Teflaro (bempedoic acid), which generated $312 million in global sales in 2025. Corstasis’ pipeline includes two additional investigational compounds with distinct mechanisms targeting atherosclerotic inflammation and cholesterol efflux. These assets are expected to complement Esperion’s existing portfolio and enhance its commercial differentiation in the $60 billion global cardiovascular therapeutics market. Market participants have reacted positively, with Esperion’s stock (ESPR) rising 8.7% in early trading following the announcement. Investors are viewing the acquisition as a strategic bet on long-term growth amid increasing demand for therapies that address residual risk in patients on statin therapy. The deal also reflects broader industry trends toward consolidation in the cardiovascular space, with major players like CVS Health (CVS) and Pfizer (PFE) actively investing in cardiovascular innovation through partnerships and acquisitions. The transaction is expected to close in the third quarter of 2026, pending customary regulatory approvals. Post-acquisition, Corstasis will operate as a wholly owned subsidiary under Esperion’s R&D division, with plans to accelerate clinical development and prepare for potential U.S. Food and Drug Administration (FDA) submissions. The integration team will focus on aligning research, manufacturing, and commercial infrastructure to support rapid advancement of the combined pipeline.